The historical approach to assessing a drug’s effect on cardiac repolarization involved conducting a costly Thorough QT (TQT) study. The guideline revision adopted in late 2015 allows the possibility to obtain reliable ECG data from early stage studies by leveraging high precision QT analysis and exposure-response modelling. Sponsors can benefit from significant cost savings and evaluate the cardiac safety of their compounds earlier in their development strategy.